1 year 0.1
Extreme 0.1
0.1
3 years 0.1
Extreme 0.1
0.1
5 years 0.1
Extreme 0.1
0.1
10 years 0.1
Extreme 0.1
0.1
Manager TitleAgeSince
Chief Executive Officer 62 2023-01-31
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 55 2017-07-31
Director TitleAgeSince
Chairman 63 2023-01-16
Chairman 78 -
Director/Board Member 63 2003-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 6.31M
+1.34%-3.97%+24.82%+9.21% 222B
+1.44%-2.53%+3.00%-20.96% 145B
+0.71%+0.39%-20.72%+19.80% 130B
+0.60%+0.42%-54.65%-9.79% 69.68B
+0.09%+0.04%+11.07%+18.91% 52.3B
+0.41%+0.51%-14.70%-13.84% 50.71B
+0.97%-2.38%+20.91%+24.18% 42.28B
+1.57%-0.48%+39.03%+46.68% 39.87B
-0.21%-2.05%-14.80%+45.03% 33.37B
Average +0.69%-1.39%-0.67%+13.25% 78.62B
Weighted average by Cap. +0.97%-2.11%+1.55%+7.08%

Financials

2024 2025
Net sales 10.51M 1.09M 942K 888K 809K 1.51M 103M 1.52M 4.08M 52.76M 4.1M 4.01M 173M 16.65M 1.73M 1.49M 1.41M 1.28M 2.39M 163M 2.41M 6.46M 83.56M 6.5M 6.35M 274M
Net income -20.18M -2.1M -1.81M -1.7M -1.55M -2.9M -198M -2.92M -7.83M -101M -7.87M -7.7M -333M -17.52M -1.82M -1.57M -1.48M -1.35M -2.52M -172M -2.54M -6.8M -87.94M -6.84M -6.69M -289M
Net Debt - -
Logo Phase Holographic Imaging PHI AB
Phase Holographic Imaging PHI AB (PHI) is a Sweden-based company active in the field of medical technology. It develops and markets time-lapse cytometers for clinical applications. The products use holographic microscopy technology, with image sensors capturing light information from objects, and computer processing the information to create visual image. It is also engaged in the development of related software. Its method allows to view and measure living cell over time, without disturbing or destroying it. PHI collaborates with cancer- and stem cell researchers, among others. The Company’s product portfolio includes HoloMonitor M3, a bench-top time-lapse cytometer, and HoloMonitor M4, allowing cell analysis in the cultivation incubator.
Employees
15
  1. Stock Market
  2. Stocks
  3. PHIX.F Stock